Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. Show more

#140, 14315 – 118 Avenue, Edmonton, AB, T5L 4S6, Canada

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.955B

52 Wk Range

$6.55 - $16.54

Previous Close

$14.83

Open

$14.69

Volume

895,001

Day Range

$14.50 - $14.96

Enterprise Value

1.249B

Cash

351.8M

Avg Qtr Burn

N/A

Insider Ownership

6.84%

Institutional Own.

55.62%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Lupkynis (Voclosporin) Details Lupus nephritis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Aritinercept (AUR200) Details Autoimmune disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Voclosporin Details Focal segmental glomerulosclerosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Voclosporin Ophthalmic Solution Details Dry eye syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.